« Return to News | R&D Trends

BioCity Scotland secures former MSD site

Wednesday, January 18, 2012 12:09 PM

Newly-formed BioCity Scotland, a centralized base for growing bioscience, pharameutical, med tech and health companies, will set up house in the former-MSD research facility at Newhouse, which it acquired Jan. 11.

A joint venture between BioCity Nottingham and Roslin BioCentre, BioCity Scotland will be 15 miles from Glasgow and 33 miles from Edinburgh, a central location for growing companies in Scotland.

The 130,000-square-foot facility consists of purpose-built labs and offices on 23 acres and is capable of supporting pre-clinical drug discovery and development by a range of independent companies. It is equipped with administrative and conference facilities to provide support and networking capabilities for client companies.

BioCity Scotland will provide access to a range of state-of-the-art equipment, available to rent at competitive rates. On-site business support will allow companies to tap into funding opportunities to assist their growing business needs.

“BioCity Scotland is much more than a property proposition—it will be a unique, vibrant community of scientific companies,” said Louis J. Nisbet, chairman of BioCity Scotland. “BioCity Nottingham's success in nurturing and growing over 70 new companies since 2003, and Roslin's expertise in life sciences innovation and facilities management makes this team the perfect commercial partnership."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.